Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report View Sample

Published: October 30, 2020 Report Code: GDHC204PIDR-ST

Select Item

Meningococcal disease is an infection caused by Neisseria meningitidis bacteria, and, although relatively rare, is widely feared because of its high mortality rate even in otherwise healthy individuals. Serogroups A, B, C, W, and Y are the most common meningococcal types in the nine major markets (9MM) covered in this report (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, and China), and immunization of high-risk groups such as infants and adolescents provides the best protection against the infection. Immunization with conjugated meningococcal serogroup C (MenC) is routinely recommended for infants in the 5EU and Brazil, and immunization against serogroup ACWY (MenACWY vaccines) is recommended in the US, UK, Italy, and Spain for adolescents, and in Argentina for infants. In China, immunization with polysaccharide MenA and MenAC vaccines is routinely recommended for infants and young children.

PR11040.png

Sanofi, GSK, and Pfizer are the major players in the meningococcal vaccine market, with GSK and Pfizer providing vaccines in each category, while Sanofi is offering only MenACWY vaccines. A major unmet need remains in a vaccine that combines the protection against all five serogroups most common in the 9MM.

Scope

  • Overview of meningococcal disease, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

  • Topline meningococcal vaccine market revenue from 2019–2029. Annual cost of immunization and major pipeline product sales in this forecast period are included.

  • Key topics covered include current vaccination options, unmet needs and opportunities, and the drivers and barriers affecting meningococcal vaccine sales in the 9MM.

  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

  • Analysis of the current and future market competition in the global meningococcal vaccine market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Questions Answered

  • How will the meningococcal vaccine market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, China) change from 2019–2029?

  • What are the most promising late-stage pipeline products for meningococcal vaccination?

  • How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing immunization options?

  • What are the remaining unmet needs in meningococcal immunization?

  • What drivers and barriers will affect meningococcal vaccine sales in the 9MM over the forecast period?

Key Highlights

During the 10-year forecast period, there are two major pipeline products that are on track to launch, driving a forecast growth in the 9MM from $3.07b in 2019 to $3.17b in 2029, which represents a CAGR of 0.3%.

To combat the unmet need of a vaccine that combines protection against all five serogroups most common in the 9MM, both GSK and Pfizer are developing combination vaccines of their respective MenB and MenACWY vaccines that are projected to launch in the second half of the forecast period to 2029. The vaccine will also reduce the infant vaccine burden, while reducing the cost of vaccination and healthcare visits. The late-stage pipeline pentavalent MenABCWY vaccines are expected to gain a market share of 21% and sales of $670M in the 9MM by 2029. However, slow changing immunization recommendations and by targeting adolescent aged 10-25 years of age, leaves room for growth in the lucrative childhood immunization market in the 5EU, Brazil, Argentina, and China, if the companies seek approval for infants.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global meningococcal vaccine market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the meningococcal vaccine market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

GlaxoSmithKline
Pfizer
Sanofi
CanSino Biologics
Beijing Tiantan Biological Products
Lanzhou Institute of Biological Products
Shanghai Institute of Biological Products
Shenzhen Sanofi Pasteur Biological Products
Walvax Biotechnology
Wuhan Institute of Biological Products

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Meningococcal Vaccines: Executive Summary

2.1 Modest Growth Expected for the Meningococcal Vaccines Market over the Forecast Period, 2019–2029

2.2 Multivalent Meningococcal Vaccines Will Shape the Market During the Forecast Period to 2029

2.3 Multivalent MenACWY Vaccines Will Provide Broader Protection While Reducing the Vaccine Burden and Being More Cost-effective

2.4 The Anticipated Launches of Pentavalent MenABCWY Vaccines in 2024 Will Slowly Change the Meningococcal Vaccine Competitive Landscape

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Meningococcal Disease (2019–2029)

5.5.1 Laboratory-Confirmed Incident Cases of IMD

5.5.2 Laboratory-Confirmed Incident Cases of IMD by Serogroup, 2019 and 2029

5.5.3 Age-Specific Laboratory-Confirmed Incident Cases of IMD

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.3 5EU

6.3.1 France

6.3.2 Germany

6.3.3 Italy

6.3.4 Spain

6.3.5 UK

6.4 Argentina

6.5 Brazil

6.6 China

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Multivalent Meningococcal Vaccines

8.3 Routine Immunization Against Multiple Meningococcal Serogroups

8.4 Long-Term Protection Against Invasive Meningococcal Disease

8.5 Improved Vaccine Cost Effectiveness

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 GlaxoSmithKline

10.4 Pfizer

10.5 Sanofi

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Argentina

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 Brazil

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

11.6 China

11.6.1 Forecast

11.6.2 Key Events

11.6.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Vaccine Coverage

12.3.3 Drugs Included in Each Vaccine Class

12.3.4 Launch Dates

12.3.5 General Pricing Assumptions

12.3.6 Individual Drug Assumptions

12.3.7 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: Meningococcal Vaccines: Key Metrics in the 9MM

Table 2: Symptoms of Meningococcal Disease

Table 3: Risk Factors and Comorbidities for Invasive Meningococcal Disease

Table 4: Vaccination Guidelines for Meningococcal Disease

Table 5: Country Profile – US

Table 6: Country Profile – France

Table 7: Country Profile – Germany

Table 8: Country Profile – Italy

Table 9: Country Profile – Spain

Table 10: Country Profile – UK

Table 11: Country Profile – Argentina

Table 12: Country Profile – Brazil

Table 13: Country Profile – China

Table 14: Leading Vaccines for Meningococcal Disease, 2020

Table 15: GSK’s Meningococcal Vaccine Portfolio Assessment, 2020

Table 16: Pfizer’s Meningococcal Vaccine Portfolio Assessment, 2020

Table 17: Sanofi’s Meningococcal Vaccine Portfolio Assessment, 2020

Table 18: Meningococcal Vaccine Market – Global Drivers and Barriers, 2019–2029

Table 19: Key Events Impacting Sales of Meningococcal Vaccines in the US, 2019–2029

Table 20: Meningococcal Vaccines Market – Drivers and Barriers in the US, 2019–2029

Table 21: Key Events Impacting Sales of Meningococcal Vaccines in the 5EU, 2019–2029

Table 22: Meningococcal Vaccines Market – Drivers and Barriers in the 5EU, 2019–2029

Table 23: Key Events Impacting Sales of Meningococcal Vaccines in Argentina, 2019–2029

Table 24: Meningococcal Vaccines Market – Global Drivers and Barriers in Argentina, 2019–2029

Table 25: Key Events Impacting Sales of Meningococcal Vaccines in Brazil, 2019–2029

Table 26: Meningococcal Vaccines Market – Global Drivers and Barriers in Brazil, 2019–2029

Table 27: Key Events Impacting Sales of Meningococcal Vaccines in China, 2019–2029

Table 28: Meningococcal Vaccines Market – Global Drivers and Barriers in China, 2019–2029

Table 29: Key Historical and Projected Launch Dates for Meningococcal Vaccines

Table 30: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for Meningococcal Vaccines in 2019 and 2029

Figure 2: Analysis of the Company Portfolio Gap in Meningococcal Vaccines During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Prophylaxis of Meningococcal Disease, 2019–2029

Figure 4: Membrane Structure of N. meningitidis

Figure 5: 9MM, Laboratory-Confirmed Incidence Rate of IMD, Cases per 100,000 Population, Men and Women, All Ages, 2009–2019

Figure 6: 9MM, Sources Used for the Laboratory-Confirmed Incident Cases of IMD

Figure 7: 9MM, Laboratory-Confirmed Incident Cases of IMD, Men and Women, All Ages, 2019, N

Figure 8: 9MM, Laboratory-Confirmed Incident Cases of IMD by Serogroup, Men and Women, All Ages, 2019, N

Figure 9: 9MM, Laboratory-Confirmed Incident Cases of IMD by Serogroup, Men and Women, All Ages, 2029, N

Figure 10: 9MM, Laboratory-Confirmed Incident Cases of IMD by Age, Men and Women, 2019

Figure 11: Unmet Needs and Opportunities in Meningococcal Vaccination

Figure 12: Overview of the Development Pipeline for Meningococcal Vaccines

Figure 13: Key Phase III Trials for the Promising Pipeline Agents that GlobalData Expects Be Licensed for Meningococcal Disease in the 9MM During the Forecast Period

Figure 14: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for Meningococcal Immunization

Figure 15: Analysis of the Company Portfolio Gap in Meningococcal Vaccines To 2029

Figure 16: Global (9MM) Sales Forecast by Country for Meningococcal Vaccines in 2019 and 2029

Figure 17: Sales Forecast by Class for Meningococcal Vaccines in the US in 2019 and 2029

Figure 18: Sales Forecast by Class for Meningococcal Vaccines in the 5EU in 2019 and 2029

Figure 19: Sales Forecast by Class for Meningococcal Vaccines in Argentina in 2019 and 2029

Figure 20: Sales Forecast by Class for Meningococcal Vaccines in Brazil in 2019 and 2029

Figure 21: Sales Forecast by Class for Meningococcal Vaccines in China in 2019 and 2029

Frequently asked questions

Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Infectious Disease reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029 in real time.

  • Access a live Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more